Aileron Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Brian Windsor
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 285 Summer Street Boston MA United States of America 02210
- IPO Date
- Jun 29, 2017
- CIK
- 0001420565
- Website
- aileronrx.com
- Similar Companies
- Business
- Aileron Therapeutics, Inc. (NASDAQ: ALRN) is a clinical-stage biopharmaceutical company that develops novel peptide-based therapeutics for pulmonary and fibrotic diseases; its lead product candidate, LTI-03, a Caveolin-1-related inhaled peptide, targets idiopathic pulmonary fibrosis (IPF) in an ongoing Phase 1b trial evaluating safety, tolerability, and biomarkers, while its second candidate, LTI-01, a proenzyme for loculated pleural effusions (LPE), has completed Phase 1b and Phase 2a trials, received Orphan Drug Designation in the US and EU, and Fast Track Designation in the US, with plans to advance to Phase 2b. The company, founded in 2001 and headquartered in Boston, Massachusetts, previously focused on stapled peptides for oncology and chemoprotection before a strategic overhaul. In late 2023, Aileron acquired Lung Therapeutics, Inc., gaining its pulmonary pipeline including LTI-01 and LTI-03, discontinued internal development of prior assets like ALRN-6924, and raised approximately $18 million through a private placement of preferred stock and warrants to fund clinical progress; subsequent financings included a May 2024 registered direct offering yielding $18.2 million in net proceeds and additional capital to extend its runway into 2025 or beyond. In January 2025, the company rebranded to Rein Therapeutics, adopting new branding to emphasize first-in-class treatments for lung diseases, and reported Phase 1b data for LTI-03 showing positive biomarker trends, with a Phase 2 trial planned for the first half of 2025.
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics to Present at the 8th Annual IPF Summit
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Aileron Therapeutics to be Included in the Russell Microcap® Index
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Aileron Therapeutics Announces CEO Transition
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024